-
Product Insights
C-C Motif Chemokine 2 – Drugs In Development, 2023
Global Markets Direct’s C-C Motif Chemokine 2 provides in depth analysis on C-C Motif Chemokine 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Motif Chemokine...
-
Product Insights
A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 – Drugs In Development, 2023
Global Markets Direct’s A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 provides in depth analysis on A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview...
-
Product Insights
C-X-3-C Motif Chemokine Receptor – Drugs In Development, 2023
Global Markets Direct’s C-X-3-C Motif Chemokine Receptor provides in depth analysis on C-X-3-C Motif Chemokine Receptor targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-3-C Motif Chemokine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LY-3873862 in Neurodegenerative Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LY-3873862 in Neurodegenerative Diseases report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LY-3873862 in Neurodegenerative Diseases Drug Details: LY-3873862 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MYMV-101 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MYMV-101 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MYMV-101 in Human Immunodeficiency Virus (HIV) Infections (AIDS)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IMCY-0141 in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMCY-0141 in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMCY-0141 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Liposarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Liposarcoma Drug Details: ATX-101 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Colorectal Cancer Drug Details: ATX-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Solid Tumor Drug Details: ATX-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Leiomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Leiomyosarcoma Drug Details: ATX-101 is under development for the treatment...